NasdaqGS:RGNXBiotechs
Regenxbio (RGNX) Q1 Loss Deepens And Reinforces Bearish Cash Runway Concerns
REGENXBIO (RGNX) Q1 2026 earnings snapshot
REGENXBIO (RGNX) has just posted Q1 2026 results with revenue of US$6.4 million and a basic EPS loss of US$1.72, against a trailing twelve month basic EPS loss of US$5.59 on revenue of US$87.8 million. Over recent quarters the company has reported revenue of US$89.0 million in Q1 2025, followed by US$21.4 million in Q4 2024. Basic EPS moved from a profit of US$0.12 in Q1 2025 to a loss of US$1.01 in Q4 2024. These figures are likely to draw investor...